Opportunity to get in on the ground floor of cannabis investment, with a Secured 12% Convertible Notes. Company is set for a 2019 NASDAQ IPO through Regulation A+ which has already been filed with the SEC.

1. Cannabinoid Biosciences Inc.
A California Corporation

2. The Cannabinoid
Biosciences
Business Plan:
A Unique Opportunity to
Build an Investment Grade
Company in the Emerging
Cannabis Industry

3. About US
• Cannabinoid Biosciences, Inc.Company:
• Frank Igwealor, CPA, JD, MBA,
CMA, CFM, MSRM Sr.
Vice President and CFO
Prepared
by:
• Biopharmaceutical Research &
Development, Investing,
Financing and Service Solutions
in the Cannabis Industry
Products:

4. OUR MARKET:
As at November 30, 2018, Thirty-three states and the District of
Columbia currently have passed laws and/or regulations that
recognize, in one form or another, legitimate medical uses for
cannabis and consumer use of cannabis in connection with medical
treatment. The District of Columbia and 10 states -- Alaska,
California, Colorado, Maine, Massachusetts, Michigan, Nevada,
Oregon, Vermont and Washington -- have adopted the most expansive
laws legalizing marijuana for recreational use. It is no wonder then
that the legal marijuana market in the U.S. is estimated to grow from
$9.2 billion in 2017 to $47.3 billion in 2027. Another report from
RBC Capital Markets showed that American cannabis sales are
quickly catching up to those of beer and wine, and the market could
be worth $47 billion within a decade.

5. REGULATION:
The regulatory environment is gradually shifting more
favorably on medical cannabis and biopharmaceutical
cannabinoid at both federal and state level. For
example, the H.R. 2, the Agriculture Improvement Act
of 2018, also known as the 2018 Farm Bill, H.R. 2
includes a provision that lift the ban on hemp, authorize
hemp production and research and amend the
Controlled Substances Act. See.
https://rules.house.gov/bill/115/hr-2. On December 12,
2018, U.S. Congress approved a Bill to Make CBD
Federally Legal. Passage of 2018 Farm Bill clarifies
CBD legal status and lets U.S. farmers grow hemp, but
some regulatory questions remain.
https://www.consumerreports.org/marijuana/will-new-
farm-bill-make-cbd-legal-everywhere/

6. CUSTOMER BASE AND
MARKET ACCEPTANCE:
• There is excitement in the air as market sentiment among
investors and customers alike in the legal marijuana industry
grows more positive. Many states are promising to deliver new
markets, reducing risk exposure from the federal government
legally intervening. This situation is creating an inviting
paradigm for investors; stabilized business environments,
breakthroughs in Congress, and shifts in federal enforcement.
Cannabis-related business such as our research and
development of cannabinoid, cannabidiol, endocannabinoids,
phytocannabinoids, and synthetic cannabinoids product
platform suitable for specific treatments, are gaining acceptance
in the eyes of the general public including the recent
pronouncements and conducts of the U.S. Food and Drug
Administration (FDA), showed that federal authorities are not
opposed to such research and development.

7. COMPETITION:
Right now there is no fund
focused on rollup of existing
high-margin dispensaries
California and across the U.S.
marketplace. In California for
example, with 358 licensed
recreational marijuana stores,
the state’s three licensing
authorities have issued over
5,000 commercial cannabis
licenses. So competition is not
an issue now.

8. OPPORTUNITIES:
• Above market data was one of the reasons that informed our
principals’ decision to raise $75 million in capital through the
Regulation D 506(c) via crowdfunding platform with which to
acquire/rollup ≥10 select dispensaries, consolidate their
operation and financial information, and IPO on the NASDAQ
or NYSE and Canadian Securities Exchange (CSE). In
addition, we are raising $50 million for acquisition of additional
8-10 dispensaries via the Regulation A+ T2. We have completed
the filings and are waiting for the U.S Securities and Exchange
Commission (SEC) to qualify our Reg. A+ Offering Circular.

9. ROLLUP OPPORTUNITY
• We’re raising $50 million through Reg A+ and $75
million via Reg. D to acquire 10 dispensaries which
we’ll rollup into our holding company and IPO on the
NASDAQ or New York Stock Exchange. Based on
the most recent large-scale buy/sell transactions in the
stock market (STZ buyinto CGC and Altria buyinto
CRON), and the fact that the market is paying on
average $131 per $1 of revenue for Cannabis
businesses, a successful rollup as contemplated would
fetch about $4.6 billion or $215 per share after
consolidation and listing on NASDAQ or NYSE.

10. Five-Year Pro Forma Financial Summary
2019 2020 2021 2022 2023
Revenue
Retail and Wholesales 54,237,238 63,544,375 74,448,621 87,224,040 102,191,728
Real Estate and Financial 372,320 1,703,880 3,420,480 4,593,480 5,383,480
Industry Turnkey Solutions 294,000 3,243,600 13,149,321 17,318,186 22,068,824
Compliance Solutions 56,000 1,329,000 4,212,000 5,122,000 7,642,000
Industry Rollup 0 0 0 60,000,000
Total Gross Revenue (USD) 54,959,558 69,820,855 95,230,422 114,257,706 197,286,032
Net profit $17,091,402 $20,024,295 $23,460,474 $27,486,303 $32,202,966
Dividend Distributions 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Reinvestments 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Projected Market
Capitalization
$4.68
Billion
$5.48
Billion
$6.42
Billion
$7.52
Billion
$8.82
Billion

11. The following summarizes the
key terms of the Secured
Convertible Notes and the private
placement. Please refer to the
relevant sections of the PPM and
related documents, including the
Company‛s articles of
incorporation (“Articles”) for
more complete details about the
Secured Convertible Notes and
the private placement.

12. Issuer Cannabinoid Biosciences, Inc.
Security Secured Convertible Note into Common Stock
Discount 20%
Interest Rate 12% Per Annum (payable fifteen days after the end of the year)
Maturity December 31st 2023
Valuation Cap N/A
Floor N/A
Minimum Subscription $1,000 per investor
Maximum Subscription $75 million per investor
Initial Closing Min. of $10K before 12/31/2019
Additional Closings One or more; up to a total of $75 million
Use of Proceeds Rollup Cannabis and fund growth across US
Dividend Declarations Dividend payment in year 4, subject to Board approval
Liquidity Event Sale of company or listing on a major stock exchange
Mandatory Conversion Converts to Shares of Common Stock
Resale Restrictions No resale permitted within 12 months & Board approval
Voting Rights Per Cannabinoid Biosciences Inc. Articles of Incorporation and By Laws
Registrar and Transfer Agent FundAmerica (VStock Transfer)
Escrow Company Prime Trust
Corporate Bank Bank of America
Legal Counsel Law Office of Azuka L Uzoh
ISIN / CUSIP To be issued
Governing Law Laws of California